A single-institution prospective pilot clinical trial was performed to demonstrate the feasibility
of combining [177Lu] Lu-PSMA-617 radiopharmaceutical therapy (RPT) with stereotactic …

Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …

As the use of radioligand therapy moves earlier in the prostate cancer timeline, minimizing
the absorbed dose to normal organs while maintaining high tumor radiation doses becomes …

Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands allow for labeling with
18F and radiometals for endoradiotherapy. rhPSMA-7.3 has been designated as a lead …

177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …

Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen
(PSMA) ligands have demonstrated promising results for the treatment of metastatic …

Introduction A targeted theragnostic approach based on increased expression of prostate-
specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients …

Simple Summary Radioligand therapy (RLT) usually consists of predefined cycles of 177Lu-
PSMA-617 every 6–8 weeks. Although side-effects of RLT are considered well tolerable …

177Lu-PSMA-617 is an effective therapeutic option in metastasized castration-resistant
prostate cancer (mCRPC). However, some patients progress under treatment. We …

Aim In patients with metastasized castration-resistant prostate cancer a reliable imaging-
based therapy response assessment in addition to PSA kinetics is desirable. Recently …